期刊文献+

慢性嗜酸粒细胞白血病/高嗜酸粒细胞综合征临床和实验室特征研究 被引量:9

Studying of clinical and laboratory features of chronic eosinophilic leukemias/hypereosinophilic syndrome
原文传递
导出
摘要 目的探讨慢性嗜酸粒细胞白血病(CEL)/高嗜酸粒细胞综合征(HES)的临床和实验室特征。方法回顾性分析20例CEL/HES患者,用筑巢式RT—PCR方法检测FIP1L1-PDGFRA融合基因;等位基因特异性聚合酶链反应(ASP—PCR)联合测序分析检测JAK2 V617F,PCR-限制性片段长度多态性(RFLP)检测JAK2V617F突变状态;PCR法检测TCRγ重排。比较CEL与HES的临床和实验室特征。结果20例患者男:女为19:1,中位年龄33(20~57)岁。12例FIP1L1-PDGFRA检测阳性,测序证实FIP1L1断裂位点位于内含子10~12,PDGFRA断裂位点位于外显子12。1例HES患者存在JAK2 V617F,突变状态分析显示为杂合子突变。6例检出TCRγ基因重排,其中CEL4例,HES2例。CEL患者以呼吸道症状起病者多见,易合并循环系统损害及神经系统症状。CEL患者脾脏肿大发生率明显高于HES(分别为92.5%和42.5%,P=0.031),发生贫血及骨髓纤维化的比例亦高于后者。外周血嗜酸粒细胞绝对值、白细胞计数、血小板计数、骨髓嗜酸粒细胞比例、骨髓原始细胞比例二组之间差异无统计学意义。嗜酸粒细胞形态学异常更多见于CEL患者,主要表现为嗜酸性颗粒减少,嗜碱性颗粒增多及胞质空泡等。结论①嗜酸粒细胞增多男性好发,以年轻人为主;②CEL患者主要表现为循环系统、呼吸道及消化道症状,易发生贫血和血小板减少,常规检查对CEL与HES鉴别意义不大,骨髓涂片形态学检查对CEL诊断有一定帮助;③部分HES患者存在JAK2 V617F突变,进一步研究其在HES发病中的作用有助于今后此类患者的诊断及开展新的靶向药物治疗;④部分CEL FIP1L1-PDGFRA融合基因TCRγ重排同时存在,二者在HES发病中的关系需进一步研究。 Objective To investigate the clinical and laboratory features of chronic eosinophilic leu- kemias(CEL) and hypereosinophilic syndrome(HES). Methods The clinical manifestations, laboratory pa- rameters were retrospectively analyzed in 20 patients with HES/CEL. Detection of the FIP1L1-PDGFRA fusion gene was performed by nested RT-PCR. JAK2 V617F mutation screening was processed through allelespecific PCR combined with sequence analysis. PCR-RFLP was used to discriminate homozygous from heterozygous mutation patterns. TCRγ rearrangement was detected by PCR. Results Of the 20 patients, 19 were males and one female, with a median age of 33(20 to 57) years. The FIP1L1-PDGFRA fusion gene positivity in bone marrow mononuclear cells in 12 cases was identified. All the breakpoints were identified by direct sequencing of cloned RT-PCR products in FIP1L1 intron 10 - 12 and in PDGFRA exon 12. In CEL the most common involved organs were lungs, heart and nervous system. Splenomegaly was significantly more frequent in CEL than in HES (92. 5% vs 42.5% , P =0. 031). Anemia and myelofibrosis were common in CEL. There was no significant difference in circulating absolute eosinophil, leukocyte, platelet counts, hemoglobin level and percentages of eosinophil and blast cell in bone marrow between CEL and HES. The morphological abnormalities of eosinophils on bone marrow smear were easily found in CEL, including hypogranularity, and cytoplasmic vacuolization, increased basophilic granule. One patient with HES was found to have heterozygous JAK2 V617F mutation. Six patients had TCRγ rearrangement, including 4 CEL and 2 HES. Conclusions (1)There is a male predominance in HES/CEL, and the median age was in the thirties. (2)The most common involved organs in CEL were lung, heart and nervous system. Bone marrow morphology might be of a little help in diagnosis of CEL. (3)JAK2 V617F may be involved in the pathogenesis of HES. (4)Patients with CEL carried the FIP1L1-PDGFRA fusion gene and TCRγ rearrangement concurrently, their relationship worrants further study.
出处 《中华血液学杂志》 CAS CSCD 北大核心 2008年第1期3-8,共6页 Chinese Journal of Hematology
基金 国家自然科学基金(30670899/C03030202) 新世纪优秀人才资助计划(NCET-05-0173)
关键词 高嗜酸粒细胞综合征 白血病 嗜酸粒细胞 慢性 FIP1L1-PDGFRA融合基因 DNA突变分析 基因重排 γ链T细胞抗原受体 Hypereosinophilic syndrome Leukemia, eosinophilic, chronic FIP1L1-PDGFRA fusion gene DNA mutation analysis Gene rearrangement, gama-chain T-cell antigen receptor
  • 相关文献

参考文献13

  • 1Hardy WR, Anderson RE. The hypereosinophilic syndromes. Ann Intern Med, 1968, 68 : 1220-1229.
  • 2Bain B, Pierre R, Imbert M, et al. Chronic eosinophilic leukaemia and the hypereosinophilic syndrome//Jaffe ES, Harris NL, Stein H, et al. World Health Organization of tumours : tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press, 2001 : 29-31.
  • 3Cools J, Deangelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1 L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med, 2003, 348 : 1201-1214.
  • 4Pongers-Willemse M J, Seriu T, Stolz F, et al. Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TALl deletions as PCR targets. Leukemia, 1999,13:110-118.
  • 5Roche-Lestienne C, Lepers S, Soenen-Cornu V, et al. Molecular characterization of the idiopathic hypereosinophilic syndrome (HES) in 35 French patients with normal conventional cytogenetics. Leukemia, 2005, 19: 792-798.
  • 6Vandenberghe P, Wlodarska I, Michanx L, et al. Clinical and molecular features of FIP1 L1-PDFGRA ( + ) chronic eosinophilic leukemias. Leukemia, 2004, 18 : 734-742.
  • 7Klion AD, Noel P, Akin C, et al. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood, 2003, 101: 4660-4666.
  • 8James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature, 2005, 434 :1144-1148.
  • 9Saharinen P, Vihinen M, Silvennoinen O. Autoinhibition of JAK2 tyrosine kinase is dependent on specific regions in its pseudokinase domain. Mol Biol Cell, 2003,14 : 1448-1459.
  • 10Wilkins H J, Crane MM, Copeland K, et al. Hypereosinophilic syndrome: an update. Am J Hematol, 2005, 80:148-157.

同被引文献45

  • 1时昊,朱锋,张红,肖爱琴,张志瑢,王克强.急性非淋巴细胞白血病中CD117表达与化疗疗效的关系[J].中国癌症杂志,2006,16(3):165-168. 被引量:4
  • 2肖志坚,郝玉书,卞寿庚,秘营昌,李建波,陈辉树,钱林生,丁现超,王岩,薛艳萍,赵耀中.8p11骨髓增殖综合征——一例报告及文献复习[J].中华血液学杂志,1996,17(11):566-568. 被引量:10
  • 3王琳娜,陈赛娟.原发性嗜酸粒细胞增多症分类诊断、发病机制和治疗研究进展[J].国际输血及血液学杂志,2006,29(5):419-422. 被引量:7
  • 4Care RS, Valk PJ, Goodeve AC, et al. Incidence and prognosis of c-kit and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias. Br J Haematol, 2003, 121:775-777.
  • 5Thiede C, Steudel C, Mohr B, et al. Analysis of FL33-activating mutation in 979 patients with acute myelogenous leukemia : association with FAB subtypes and identification of a sugroups with poor prognosis. Blood, 2002, 99:4326-4335.
  • 6Meshinehi S, Stirewalt DL, Alonzo TA, et al. Activating mutations of RTK/ras signal transduction pathway in pediatric acute myeloid leukemia. Blood, 2003, 102:1474-1479.
  • 7Wang YY, Zhou GB, Yin T, et al. AML1-ETO and c-kit mutation over-expression in t(8;21) leukemia: Implication in stepwise leukemogenesis and response to Gleevec. Proc Natl Acad Sci U S A, 2005, 102: 1104-1109.
  • 8Paschka P, Marcucci G, Ruppert AS, et al. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv( 16 ) and t (8;21 ) : a Cancer and Leukemia Group B Study. J Clin Oncol, 2006, 24:3904-3911.
  • 9Cairoli R, Beghini A, Grillo G, et al. Prognostic impact of c-kit mutations in core binding factor leukemias: an Italian retrospective study. Blood, 2006, 107:3463-3468.
  • 10Lee JW, Kim YG, Soung YH, et al. The JAK2 V617F mutation in de novo acute myelogenous leukemias. Oncogene, 2006, 25: 1434-1436.

引证文献9

二级引证文献97

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部